Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) EBITDA: 2013-2024

Historic EBITDA for CytomX Therapeutics (CTMX) over the last 12 years, with Dec 2024 value amounting to $31.8 million.

  • CytomX Therapeutics' EBITDA fell 344.95% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 101.55%. This contributed to the annual value of $31.8 million for FY2024, which is 6670.45% up from last year.
  • As of FY2024, CytomX Therapeutics' EBITDA stood at $31.8 million, which was up 6,670.45% from -$484,000 recorded in FY2023.
  • In the past 5 years, CytomX Therapeutics' EBITDA ranged from a high of $31.8 million in FY2024 and a low of -$116.1 million during FY2021.
  • Moreover, its 3-year median value for EBITDA was -$484,000 (2023), whereas its average is -$22.6 million.
  • Per our database at Business Quant, CytomX Therapeutics' EBITDA slumped by 78.77% in 2021 and then surged by 6,670.45% in 2024.
  • Yearly analysis of 5 years shows CytomX Therapeutics' EBITDA stood at -$64.9 million in 2020, then plummeted by 78.77% to -$116.1 million in 2021, then grew by 14.65% to -$99.1 million in 2022, then soared by 99.51% to -$484,000 in 2023, then spiked by 6,670.45% to $31.8 million in 2024.